Search results
Results from the WOW.Com Content Network
Guanfacine, sold under the brand name Tenex (immediate-release) and Intuniv (extended-release) among others, is an oral alpha-2a agonist medication used to treat attention deficit hyperactivity disorder (ADHD) and high blood pressure.
send or dispense, e.g. number of tablets provided Can be confused with m,. misce, context-dependent mane: mane: in the morning max. maximum maximum mcg microgram: recommended replacement for "μg" which may be confused with "mg" mdi metered dose inhaler m.d.u. more dicto utendus: to be used as directed mEq milliequivalent mg milligram mg/dL
Oral LD 50: Up to and including 50 mg/kg From 50 to 500 mg/kg From 500 to 5000 mg/kg Greater than 5000 mg/kg Inhalation LC50 Up to and including 0.2 mg/L From 0.2 to 2 mg/L From 2. to 20 mg/L Greater than 20 mg/L Dermal LD50 Up to and including 200 mg/kg From 200 to 2000 mg/kg From 2000 to 20,000 mg/kg Greater than 20,000 mg/kg Eye Effects
EE/CPA comes in the form of oral tablets and contains 35 or 50 μg EE and 2 mg CPA per tablet. [2] It is taken once daily for 21 days, followed by a 7-day free interval. [ 2 ]
Naldemedine, sold under the brand name Symproic in the US and Rizmoic in the European Union, is a medication that is used for the treatment of opioid-induced constipation in adults who have previously been treated with a laxative in the European Union, or to treat opioid induced constipation in adults with chronic non-cancer pain in the US.
Get answers to your AOL Mail, login, Desktop Gold, AOL app, password and subscription questions. Find the support options to contact customer care by email, chat, or phone number.
Mazindol is used in short-term (i.e., a few weeks) treatment of obesity, in combination with a regimen of weight reduction based on caloric restriction, exercise, and behavior modification in people with a body mass index greater than 30, or in those with a body mass index greater than 27 in the presence of risk factors such as hypertension, diabetes, or hyperlipidemia.
From January 2008 to December 2012, if you bought shares in companies when M. Frances Keeth joined the board, and sold them when she left, you would have a -1.4 percent return on your investment, compared to a -2.8 percent return from the S&P 500.